Speakers
Evdokia Anagnostou MD, FRCPC
Vice President of Research and Director, Holland Bloorview Research Institute and Child Neurologist
Dr. Evdokia Anagnostou is a Child Neurologist and Professor of Pediatrics at the University of Toronto and Vice President of Holland Bloorview’s Research Institute. As a Senior Clinician Scientist, she co-leads the Autism Research Centre (ARC) at Holland Bloorview and University of Toronto. She holds the Canada Research Chair in Translational therapeutics in Autism Spectrum Disorder (ASD) and the Dr. Stuart D. Sims Chair in Autism at Holland Bloorview. Most recently she has been elected as a fellow of the Canadian Academy of Health Sciences.
Dr. Anagnostou has received extensive international funding to understand the underlying biological differences associated with ASD and other neurodevelopmental differences, translate such understandings into potential novel interventions. She is also funding health system innovation, stakeholder engagement, and in understanding the meaning and impact of ASD in marginalized populations. She serves on multiple government committees on improving diagnostic and intervention pathways, and several editorial boards and grant review panels. She has also been recognized for her contributions to training young clinicians and scientists and for her commitment to women in STEM. She currently represents the region of America – North on the INSAR Global Senior Leaders committee.
Darcy Fehlings MD, MSc, FRCPC
Senior Clinician Scientist, Holland Bloorview Kids Rehabilitation Hospital and Developmental Pediatrician
Dr. Darcy Fehlings is a Developmental Paediatrician and Professor in the Department of Paediatrics at the University of Toronto. She is a Senior Clinician Scientist in the Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital. Her clinical and research work focuses on the innovation and evaluation of interventions for children with cerebral palsy and physical neurodisabilities including hypertonia interventions, early detection, constraint therapy, dystonia and pain management.
As scientific lead for CP-NET (a large translational neuroscience network focused on individuals with cerebral palsy), a large clinical database of over 900 children with CP has been created with data platforms including risk factors, neurodevelopmental functioning, brain imaging, genomics and psychosocial/quality of life.
She has led the AACPDM Care Pathway for ‘Dystonia in CP.’ She has held positions as the inaugural head of the Division of Developmental Paediatrics, University of Toronto (2006-22), Chair of the Royal College of Physicians and Surgeons of Canada Specialty Committee of Developmental Pediatrics (2018-2024) and President of the American Academy of Cerebral Palsy and Developmental Medicine (2015).
Scientific Planning Committee
Golda Milo-Manson MD, FRCPC
Program Director
Dr. Golda Milo-Manson is a developmental paediatrician and Associate Professor in the Department of Paediatrics at the Temerty Faculty of Medicine, University of Toronto. She is also Vice-President of Medicine and Academic Affairs, Holland Bloorview Kids Rehabilitation Hospital. Dr. Milo-Manson has worked in paediatric rehabilitation for more than 20 years, largely with children and youth with physical disabilities as well as complex sleep disorders.
Faculty Disclosure
It is the policy of the University of Toronto, Temerty Faculty of Medicine, Continuing Professional Development to ensure balance, independence, objectivity, and scientific rigor in all its individually accredited or jointly accredited educational programs.
Speakers and/or planning committee members, participating in University of Toronto accredited programs, are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains but is not limited to relationships within the last TWO (2) years with not-for-profit organizations, pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic.
The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of facts.
It remains for the audience to determine whether the speaker’s outside interests may reflect a possible bias in either the exposition or the conclusions presented.
